1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Prescient Therapeutics Limited

Prescient Therapeutics Limited

PSTTF
Prescient Therapeutics LimitedUS flagOther OTC
0.15
USD
- -
- -
117.53MMarket Cap
Prescient Therapeutics Limited
PSTTF
(Other OTC)

Recent

price

0.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Similar Companies
Restart Life Sciences Corp. (HEAL.CN)
Noile-Immune Biotech Inc. (4893.T)
Pulike Biological Engineering, Inc. (603566.SS)
Forte Biosciences, Inc. (FBRX)
Mineralys Therapeutics, Inc. (MLYS)
Awakn Life Sciences Corp. (AWKNF)
Business
Prescient Therapeutics Limited (Ticker: PSTTF) is an Australian clinical-stage oncology company developing targeted cell therapies and nanoparticle drug conjugates for cancer treatment. The company offers proprietary platforms including the proprietary Cell-in-a-Box® encapsulation technology for targeted delivery of therapeutic cells; nanoparticle-based drug formulations such as PTX-200, a reformulated paclitaxel monoester in monotherix nanoparticles for multi-drug resistant cancers; and investigational products like PTX-100, a novel depsipeptide in Phase 1/2 trials for lymphoma and solid tumors. These offerings focus on precision oncology, targeting solid tumors and hematological malignancies through improved drug delivery, reduced toxicity, and enhanced efficacy; the company serves pharmaceutical partners, clinical trial sites, and oncology patients globally. Founded in 2003 and headquartered in Melbourne, Australia, Prescient Therapeutics operates primarily in Australia, the United States, and Europe, with research collaborations in North America. In 2024, the company announced a strategic rebranding to PTX Therapeutics to reflect its evolution toward next-generation targeted therapies, alongside progress in Phase 2 trials for PTX-200 in metastatic breast cancer and new partnerships for Cell-in-a-Box® technology licensing in Asia; additionally, it secured A$10 million in funding through an entitlement offer to support clinical expansion and manufacturing scale-up.

Company News

APIChatGPT